NeoGenomics Inc (NEO)
8.685
+0.30 (+3.52%)
USD |
NASDAQ |
May 19, 15:55
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 1.084B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -77.72% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 2.234 |
| Price to Book Value | 1.008 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.496 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 84.22% |
News
Headline
Wire
Time (ET)
Accesswire
05/10 02:00
Yahoo
05/09 07:00
Yahoo
05/05 06:53
Globe Newswire
05/01 21:00
MT Newswires
04/28 14:30
MT Newswires
04/28 12:37
Events
| DATE | TIME | TYPE | PERIOD | REPORTED EPS |
ESTIMATED EPS |
SURPRISE | |
| 08/05/2022* | -- | Results | Q2 2022 | -- | -0.22 | -- | |
| 08/05/2022* | 08:30 EST | Earnings Call | Q2 2022 | -- | -- | -- | |
| 04/27/2022 | -- | Results | Q1 2022 | -- | -0.24 | -- | |
| 04/27/2022 | 08:30 EST | Earnings Call | Q1 2022 | -- | -- | -- | |
| 02/23/2022 | -- | Results | Q4 2021 | -0.14 | -0.15 | 3.75% | |
| 02/23/2022 | 08:30 EST | Earnings Call | Q4 2021 | -- | -- | -- | |
| 11/04/2021 | -- | Results | Q3 2021 | -0.08 | -0.09 | 6.79% | |
| 11/04/2021 | 08:30 EST | Earnings Call | Q3 2021 | -- | -- | -- |
*Estimated Date/Time
Earnings
Profile
Edit
| NeoGenomics Inc operates a network of cancer-focused genetic testing laboratories in the United States as well as a laboratory in Switzerland. The company operates into two segments namely Clinical Services and Pharma Services. It offers types of genetic and molecular testing services namely Cytogenetics, Fluorescence In-Situ Hybridization, Flow cytometry, Immunohistochemistry, Molecular testing, Pathology consultation. The company generates revenue from Clinical Services. |
| URL | https://www.neogenomics.com |
| Investor Relations URL | https://ir.neogenomics.com/ |
| HQ State/Province | Florida |
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Equity Style | Small Cap/Blend |
| Next Earnings Release | Aug. 05, 2022 (est.) |
| Last Earnings Release | Apr. 27, 2022 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Dividends
| Dividend Per Share (TTM) | -- |
|
2017
2018
2019
2020
2021
6.00%
4.00%
2.00%
|
|
| Yield to Market | 0.00 |
| Yield to Sector | 0.00 |
| Yield to Industry | 0.00 |
| Last Dividend Amt. | -- |
| Dividend Frequency | -- |
| Last Ex-Dividend Date | -- |
| Yield (TTM) | 0% |
| Forward Yield | -- |
| Payout Ratio | 0.00% |
| Cash Payout Ratio | 0.00% |
| Consistent Payer (5Y) | No |
| Consistent Growth (5Y) | No |
Risk Info
Total Returns Comparison
Annual Total Returns Versus Peers
As of May 18, 2022.
Fundamentals
| Revenue (TTM) | 485.96M |
| Total Expenses (TTM) | 641.64M |
| Net Income (TTM) | -35.64M |
| Total Assets (Quarterly) | 1.830B |
| Total Liabilities (Quarterly) | 754.54M |
| Shareholders Equity (Quarterly) | 1.075B |
| Cash from Operations (TTM) | -57.97M |
| Cash from Investing (TTM) | -465.63M |
| Cash from Financing (TTM) | 206.41M |
Ratings
Profile
Edit
| NeoGenomics Inc operates a network of cancer-focused genetic testing laboratories in the United States as well as a laboratory in Switzerland. The company operates into two segments namely Clinical Services and Pharma Services. It offers types of genetic and molecular testing services namely Cytogenetics, Fluorescence In-Situ Hybridization, Flow cytometry, Immunohistochemistry, Molecular testing, Pathology consultation. The company generates revenue from Clinical Services. |
| URL | https://www.neogenomics.com |
| Investor Relations URL | https://ir.neogenomics.com/ |
| HQ State/Province | Florida |
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Equity Style | Small Cap/Blend |
| Next Earnings Release | Aug. 05, 2022 (est.) |
| Last Earnings Release | Apr. 27, 2022 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Risk Info
Ownership
| Insider Ownership Percentage | Upgrade |
Jul '20
Nov '20
Mar '21
80.00%
40.00%
10.00%
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Other Resources
| Whale Wisdom | 13F Filings |
| Seeking Alpha | Call Transcripts |
| Morningstar | Insider Trading |
| Nasdaq | Institutional Ownership |
| Nasdaq | Option Chain |
| SEC | SEC Filings |
| NEO Tweets |